Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 87

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 87
---
     | Position(s)                                            |
| Ronen Twito                 |     |  50 |     | Executive Chairman nominee and Chief Executive Officer |
| Prof. Michel Revel, MD, PhD |     |  86 |     | Director nominee and Chief Scientific Officer          |
| Olivier Samuel              |     |  51 |     | Independent Director                                   |
| Eran Iohan                  |     |  54 |     | Independent Director nominee                           |
| Liora Oren                  |     |  47 |     | Independent Director nominee                           |
| Alexander C. Zwyer          |     |  55 |     | Director                                               |
| Tammy Galili                |     |  52 |     | Director nominee                                       |

Certain Material Swiss Tax Considerations (Page 205) For a description of certain material Swiss tax consequences of the Merger and the ownership and disposition of NLS Common Shares, see the section entitled “ Tax Considerations — Switzerland Tax Considerations”.

17 Risk Factors (Page 24) In evaluating the proposals to be presented at the NLS Meeting, a shareholder should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section entitled “Risk Factors” in this proxy statement/prospectus. These risks are summarized below. Summary of Risk Factors Investing in our common shares and Warrants involves substantial risks. Our ability to execute our strategy is also subject to certain risks. The risks described below may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. In particular, our risks include, but are not limited to, the following summary of such risk factors: Risks Related to Our Business •We may be unable to successfully use mazindol, on which we depend substantially, as the drug substance for each of our current clinical mid -stageproduct candidates, Quilience, for the treatment of narcolepsy, and Nolazol, for the treatment of ADHD, and which outcome could prove costly to our business and could prevent us from obtaining regulatory or marketing approval; •We may not be able to initiate our Phase 3 clinical trials in Quilience without additional pre -clinicalstudies, chemistry, manufacturing, controls, work or early -stageclinical trials; •Prior results of mazindol for the treatment of other indications may not be replicated in the clinical trials that we conduct for the treatment of narcolepsy or ADHD; and •If, and when,